Not provided
Not provided
Not provided
Not provided
Not provided
Financial concerns with device manufacturer.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study will document efficacy and safety of the Axiom Worldwide DRX9000â„¢ for treatment of low back pain (LBP) in a prospective, randomized, crossover, multicenter trial utilizing a standardized clinical research multimodal protocol. During the first two weeks subjects are randomized to receive either conservative care or DRX treatment first and then cross over to receive either conservative care or DRX treatment the next 6 weeks. This study will test the hypothesis that standardized 6-week treatment regimen of spinal decompression using DRX9000â„¢ will reduce chronic lower back pain more than conservative therapy (current baseline therapy).
This study will document efficacy and safety of the Axiom Worldwide DRX9000â„¢ for treatment of low back pain (LBP) in a prospective, randomized, crossover, multicenter trial utilizing a standardized clinical research multimodal protocol. During the first two weeks subjects are randomized to receive either conservative care or DRX treatment first and then cross over to receive either conservative care or DRX treatment the next 6 weeks. This study will test the hypothesis that standardized 6-week treatment regimen of spinal decompression using DRX9000â„¢ will reduce chronic lower back pain more than conservative therapy (current baseline therapy
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| DRX Treatment | Experimental | 20 treatments of spinal decompression over a six week period. Each session lasts about 45 minutes and consists of a 28-minute treatment on the DRX9000â„¢ machine followed by 15 minutes of cold therapy to the lumbar paravertebral muscles. |
|
| Conservative Care | No Intervention | Conservative non surgical therapy for 6 weeks prior to beginning DRX9000 treatment |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| DRX9000â„¢ | Device | Nonsurgical spinal decompression |
|
| Measure | Description | Time Frame |
|---|---|---|
| The primary outcome measure is lower back pain measured on an 11-point numeric rating scale (VRS) with 0 reflecting no pain at all and 10 the worst imaginable pain. | 1 year |
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of adverse events | 1 year | |
| Recurrence rate, measured by the proportion of patients with VRS ≥ 4 | 1 year | |
| Proportion of patients using adjuvant analgesic medication |
Not provided
Inclusion Criteria:
In addition to a diagnosis of LBP, ALL of the following criteria must be met:
Exclusion Criteria:
If ANY of the following exclusion criteria are present, the subject is NOT eligible:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Joseph V Pergolizzi, MD | NEMA Research, Inc. | Principal Investigator |
| Charlotte Richmond, PhD | NEMA Research, Inc. | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Johns Hopkins Bayview Medical Center | Baltimore | Maryland | 21224 | United States |
Not provided
| ID | Term |
|---|---|
| D017116 | Low Back Pain |
| ID | Term |
|---|---|
| D001416 | Back Pain |
| D010146 | Pain |
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| 1 year |
| Functional capacity, measured by the established Oswestry Disability Index | 1 year |
| Patient's satisfaction with procedures and treatment | 1 year |
| D013568 |
| Pathological Conditions, Signs and Symptoms |